Product information and disease description
Place of product in therapy
31 evidence topics · 26 sources
Ivonescimab
EGFR-mutated non-small-cell lung cancer
- Manufacturer
- Summit Therapeutics
- Regulatory submission
- BLA submitted in the fourth quarter of 2025
- Launch
- Not announced
- Last updated